Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
January 10, 2025
January 10, 2025
NEW BRUNSWICK, New Jersey, Jan. 10 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations
Fast Track designations reinforce J&J's commitment to Alzheimer's disease development and the potential of its precision approach
* * *
TITUSVILLE . . .
* * *
Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations
Fast Track designations reinforce J&J's commitment to Alzheimer's disease development and the potential of its precision approach
* * *
TITUSVILLE . . .